Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) – Analysts at Jefferies Financial Group increased their FY2022 earnings per share estimates for Vanda Pharmaceuticals in a report issued on Monday, August 29th. Jefferies Financial Group analyst C. Howerton now forecasts that the biopharmaceutical company will post earnings of $0.22 per share for the year, up from their previous estimate of $0.18. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is $0.18 per share. Jefferies Financial Group also issued estimates for Vanda Pharmaceuticals' FY2023 earnings at $0.29 EPS, FY2024 earnings at $0.39 EPS, FY2025 earnings at $0.48 EPS and FY2026 earnings at $0.75 EPS.
Get
Vanda Pharmaceuticals alerts:
Separately, StockNews.com raised Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Friday, June 3rd.
Vanda Pharmaceuticals Stock Performance
Shares of VNDA stock opened at $10.81 on Thursday. Vanda Pharmaceuticals has a 1 year low of $9.24 and a 1 year high of $21.44. The stock has a market cap of $611.42 million, a PE ratio of 54.05 and a beta of 0.47. The stock has a fifty day moving average price of $10.83 and a 200 day moving average price of $10.89.
Insider Transactions at Vanda Pharmaceuticals
In other news, CMO Joakim Wijkstrom sold 3,605 shares of the business's stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $10.27, for a total value of $37,023.35. Following the completion of the transaction, the chief marketing officer now directly owns 96,673 shares of the company's stock, valued at $992,831.71. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CMO Joakim Wijkstrom sold 3,605 shares of the company's stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $10.27, for a total value of $37,023.35. Following the completion of the transaction, the chief marketing officer now directly owns 96,673 shares in the company, valued at $992,831.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stephen Ray Mitchell sold 2,700 shares of the company's stock in a transaction on Monday, June 13th. The shares were sold at an average price of $9.48, for a total value of $25,596.00. Following the completion of the transaction, the director now owns 6,515 shares of the company's stock, valued at $61,762.20. The disclosure for this sale can be found here. Insiders sold a total of 8,544 shares of company stock valued at $87,181 over the last three months. 7.00% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Vanda Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the business. Royce & Associates LP increased its stake in Vanda Pharmaceuticals by 99.2% in the first quarter. Royce & Associates LP now owns 239,627 shares of the biopharmaceutical company's stock valued at $2,710,000 after purchasing an additional 119,329 shares during the last quarter. Citigroup Inc. grew its position in Vanda Pharmaceuticals by 62.7% during the fourth quarter. Citigroup Inc. now owns 151,874 shares of the biopharmaceutical company's stock valued at $2,383,000 after acquiring an additional 58,518 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in Vanda Pharmaceuticals during the first quarter valued at about $119,000. Comerica Bank grew its position in Vanda Pharmaceuticals by 2.5% during the first quarter. Comerica Bank now owns 47,706 shares of the biopharmaceutical company's stock valued at $537,000 after acquiring an additional 1,180 shares during the period. Finally, ProShare Advisors LLC grew its position in Vanda Pharmaceuticals by 6.0% during the fourth quarter. ProShare Advisors LLC now owns 21,558 shares of the biopharmaceutical company's stock valued at $337,000 after acquiring an additional 1,214 shares during the period. 99.42% of the stock is currently owned by institutional investors and hedge funds.
Vanda Pharmaceuticals Company Profile
(Get Rating)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Further Reading
- Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
